Compare CYPH & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYPH | EDD |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 353.9M |
| IPO Year | 2019 | N/A |
| Metric | CYPH | EDD |
|---|---|---|
| Price | $2.00 | $5.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.3M | 322.9K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | ★ 103.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $408.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $4.96 |
| 52 Week High | $4.19 | $6.18 |
| Indicator | CYPH | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 42.88 |
| Support Level | $0.65 | $5.13 |
| Resistance Level | $3.42 | $5.61 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 7.69 | 15.87 |
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.